London (PRWEB) October 29, 2013
TechNavio analysts forecast the Global Melanoma Therapeutics market to grow at a CAGR of 15.83 percent over the period 2012-2016. One of the key factors contributing to this market growth is the availability of new promising drugs in the pipeline. The Global Melanoma Therapeutics market has also been witnessing the increasing use of combination therapies for the treatment of melanoma. However, the availability of alternative treatment options could pose a challenge to the growth of this market.
TechNavio's report, the Global Melanoma Therapeutics market 2012-2016, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Global Melanoma Therapeutics market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
The key vendors dominating this market space are Bristol-Myers Squibb Co., Merck and Co. Inc., and F. Hoffmann-La Roche Ltd.
The Other vendors mentioned in the report are AB Science S.A., Amgen Inc., Celgene Corp., Daiichi Sankyo Co., Eisai Co. Ltd., GlaxoSmithKline plc, Pfizer Inc., and Vical Inc.
Key questions answered in this report:
What will the market size be in 2016 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?
Research methodology is based on extensive primary and secondary research. Primary research includes in-depth interviews with industry experts, vendors, resellers and customers. Secondary research includes Technavio Platform, industry publications, company re
Copyright©2012 Vocus, Inc.
All rights reserved